Who are MTX + 5-FU sequential therapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Intrathecal injection of pemetrexed, Pemetrexed + oral folinic acid rescue, Unitrim, Trifluridine/Tipracil, Pemetrexed Disodium Heptahydrate, Pemetrexed + cisplatin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mtx-5-fu-sequential-therapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

MTX + 5-FU sequential therapy — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MTX + 5-FU sequential therapy (MTX + 5-FU sequential therapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimetabolite combination chemotherapy. Area: Oncology.

phase 3 Antimetabolite combination chemotherapy Thymidylate synthase, dihydrofolate reductase Oncology Small molecule Live · refreshed every 30 min

Target snapshot

MTX + 5-FU sequential therapy (MTX + 5-FU sequential therapy) — Japan Clinical Oncology Group. MTX + 5-FU sequential therapy combines methotrexate and 5-fluorouracil administered in sequence to inhibit nucleotide synthesis and DNA replication in cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
MTX + 5-FU sequential therapy TARGET	MTX + 5-FU sequential therapy	Japan Clinical Oncology Group	phase 3	Antimetabolite combination chemotherapy	Thymidylate synthase, dihydrofolate reductase
Intrathecal injection of pemetrexed	Intrathecal injection of pemetrexed	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	marketed	Antifolate antimetabolite	Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase
Pemetrexed + oral folinic acid rescue	Pemetrexed + oral folinic acid rescue	Radboud University Medical Center	marketed	Antifolate antimetabolite	Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase
Unitrim	BRODIMOPRIM		marketed	brodimoprim	Bifunctional dihydrofolate reductase-thymidylate synthase, Dihydrofolate reductase
Trifluridine/Tipracil	Trifluridine/Tipracil	Australasian Gastro-Intestinal Trials Group	phase 3	Antiviral	Thymidylate synthase, Dihydrofolate reductase
Pemetrexed Disodium Heptahydrate	Pemetrexed Disodium Heptahydrate	ECOG-ACRIN Cancer Research Group	phase 3	Antimetabolite; multitargeted antifolate	Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase
Pemetrexed + cisplatin	Pemetrexed + cisplatin	AstraZeneca	phase 3	Antifolate antimetabolite + platinum-based alkylating agent	Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase (pemetrexed); DNA (cisplatin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimetabolite combination chemotherapy class)

Japan Clinical Oncology Group · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MTX + 5-FU sequential therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/mtx-5-fu-sequential-therapy. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing